China Pharma Holdings (CPHI) Payables (2010 - 2026)

China Pharma Holdings (CPHI) has reported Payables for 17 consecutive years, with $4.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 13.56% year-over-year to $4.3 million; the trailing twelve-month figure through Jun 2026 stood at $4.3 million (up 13.56% YoY), and the FY2025 full-year result was $4.0 million, up 20.14% from the prior year.
• Payables climbed to $4.3 million in Q2 2026 per CPHI's latest filing, from $4.1 million in the prior quarter.
• Across five years, Payables topped out at $6.4 million in Q3 2022 and bottomed at $1.8 million in Q1 2022.
• Historically, Payables has averaged $3.7 million across 5 years, with a median of $3.7 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Payables surged 270.31% in 2022, then tumbled 56.03% in 2024.
• Over 5 years, Payables stood at $6.2 million in 2022, then plunged by 44.81% to $3.4 million in 2023, then dropped by 2.59% to $3.3 million in 2024, then rose by 20.14% to $4.0 million in 2025, then grew by 6.58% to $4.3 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $4.3 million, $4.1 million, and $4.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.